Safety and Tolerability of Inhaled Heparin in Idiopathic Pulmonary Fibrosis
- 29 January 2010
- journal article
- clinical trial
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 23 (3) , 161-172
Abstract
Background: Abnormalities in alveolar coagulation occur in idiopathic pulmonary fibrosis (IPF). Anticoagulants attenuate bleomycin-induced lung fibrosis in animals. In this study, we first examined the pharmacokinetics of inhaled heparin in healthy subjects. Second, we investigated the safety and tolerability of heparin inhalation in IPF patients. Methods: Coagulation assays were performed in blood and bronchoalveolar lavage fluid samples from 19 healthy volunteers after inhalation of increasing amounts of unfractionated heparin. The acute effects of heparin inhalation on lung function and exercise capacity and the safety and tolerability of chronic heparin inhalation for 28 days were assessed in 20 IPF patients in an open-label exploratory pilot study. Results: In healthy subjects, inhalation of 150,000 IU heparin (“filled dose”) significantly increased the partial thromboplastin time and anti-factor Xa activity in blood samples indicating the threshold dose. The local alveolar anticoagulant effect was detectable up to 72 h, and the alveolar half-life was estimated at 28 h. In IPF-patients, no acute deleterious effects on pulmonary function, gas exchange, or exercise capacity were noted after inhalation of the threshold dose. During chronic treatment, where one-fourth of the threshold dose was inhaled every 12 h for 28 days to obtain a steady-state anticoagulant activity in the alveolar space approximating the anticoagulant activity observed after threshold dose inhalation, no heparin-related side effects, such as hemoptysis or heparin-induced antibodies and thrombocytopenia, were detected in any patient, and median lung function values, exercise capacity, and quality of life scores appeared largely unaltered. Three adverse and one serious adverse events were noted; however, the relation of these events to the heparin inhalation was assessed as “unlikely” or “no relation” in each case. Conclusions: Inhaled heparin appears to be safe and well tolerated in IPF patients. Future clinical trials are required to demonstrate the long-term safety and efficacy of inhaled heparin in IPF.Keywords
This publication has 45 references indexed in Scilit:
- A phase 1 trial of nebulised heparin in acute lung injuryCritical Care, 2008
- Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalationClinical Science, 2008
- Inhaled heparin in cystic fibrosisEuropean Respiratory Journal, 2006
- Peripheral deposition of α1‐protease inhibitor using commercial inhalation devicesEuropean Respiratory Journal, 2003
- Effect of inhaled heparin on lung function and coagulation in healthy volunteersEuropean Respiratory Journal, 2002
- Thrombin Differentiates Normal Lung Fibroblasts to a Myofibroblast Phenotype via the Proteolytically Activated Receptor-1 and a Protein Kinase C-dependent PathwayJournal of Biological Chemistry, 2001
- Direct Thrombin Inhibition Reduces Lung Collagen, Accumulation, and Connective Tissue Growth Factor mRNA Levels in Bleomycin-Induced Pulmonary FibrosisThe American Journal of Pathology, 2001
- Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitisThe Lancet, 1996
- Aerosolized HeparinJournal of Aerosol Medicine, 1994
- INTRAPULMONARY HEPARIN A New Procedure for Anticoagulant TherapyThe Lancet, 1976